Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 539

1.

Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity.

Nissen MD, Kusakabe M, Wang X, Simkin G, Gracias D, Tyshchenko K, Hill A, Meskas J, Hung S, Chavez EA, Ennishi D, Aoki T, Sarkozy C, Connors JM, Farinha P, Slack GW, Gascoyne RD, Brinkman RR, Scott DW, Steidl C, Weng AP.

Cytometry A. 2019 Oct 22. doi: 10.1002/cyto.a.23919. [Epub ahead of print]

PMID:
31637838
2.

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.

Kaloyannidis P, Hertzberg M, Webb K, Zomas A, Schrover R, Hurst M, Jacob I, Nikoglou T, Connors JM.

Br J Haematol. 2019 Oct 6. doi: 10.1111/bjh.16201. [Epub ahead of print]

PMID:
31588564
3.

Using Plasma and Prothrombin Complex Concentrates.

Levy JH, Ghadimi K, Waldron NH, Connors JM.

Semin Thromb Hemost. 2019 Sep 19. doi: 10.1055/s-0039-1695736. [Epub ahead of print]

PMID:
31537028
4.

Anticoagulation for Subsegmental Pulmonary Embolism.

Fernandes A, Connors JM, Carrier M.

N Engl J Med. 2019 Sep 19;381(12):1171-1174. doi: 10.1056/NEJMclde1907665. No abstract available.

PMID:
31532966
5.

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.

McLaughlin K, Rimsans J, Sylvester KW, Fanikos J, Dorfman DM, Senna P, Connors JM, Goldhaber SZ.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619876030. doi: 10.1177/1076029619876030.

PMID:
31530176
6.

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel.

Lancet Oncol. 2019 Oct;20(10):e566-e581. doi: 10.1016/S1470-2045(19)30336-5. Epub 2019 Sep 3. Review.

PMID:
31492632
7.

Transgender patients and the role of the coagulation clinician.

Connors JM, Middeldorp S.

J Thromb Haemost. 2019 Aug 29. doi: 10.1111/jth.14626. [Epub ahead of print] Review.

PMID:
31465627
8.

Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients.

Song AB, Rosovsky RP, Connors JM, Al-Samkari H.

Vasc Health Risk Manag. 2019 Jun 21;15:175-186. doi: 10.2147/VHRM.S132556. eCollection 2019. Review.

9.

Thrombophilia evaluation in pulmonary embolism.

Stern RM, Al-Samkari H, Connors JM.

Curr Opin Cardiol. 2019 Nov;34(6):603-609. doi: 10.1097/HCO.0000000000000668.

PMID:
31389825
10.

Coordinating emergent procedures after andexanet alfa.

Culbreth SE, Sylvester KW, Rimsans J, Connors JM.

Am J Hematol. 2019 Oct;94(10):E278-E282. doi: 10.1002/ajh.25587. Epub 2019 Aug 10. No abstract available.

PMID:
31342554
11.

Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy?

Levy JH, Ghadimi K, Faraoni D, van Diepen S, Levy B, Hotchkiss R, Connors JM, Iba T, Warkentin TE.

J Thromb Haemost. 2019 Jul 13. doi: 10.1111/jth.14566. [Epub ahead of print] No abstract available.

PMID:
31334603
12.

Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.

Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, Gerrie AS, Ferguson D, Cafferty F, Slack GW, Farinha P, Skinnider B, Connors JM, Sehn LH.

Blood. 2019 Aug 29;134(9):761-764. doi: 10.1182/blood.2019000258. Epub 2019 Jul 12.

PMID:
31300404
13.

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.

Mottok A, Hung SS, Chavez EA, Woolcock B, Telenius A, Chong LC, Meissner B, Nakamura H, Rushton C, Viganò E, Sarkozy C, Gascoyne RD, Connors JM, Ben-Neriah S, Mungall A, Marra MA, Siebert R, Scott DW, Savage KJ, Steidl C.

Blood. 2019 Sep 5;134(10):802-813. doi: 10.1182/blood.2019001126. Epub 2019 Jul 10.

PMID:
31292115
14.

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.

Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, Gould C, Birch S, Sehn LH, Sovani V, Ward MS, Augustson B, Biccler J, Connors JM, Scott DW, Gandhi MK, Savage KJ, El-Galaly T, Villa D, Cheah CY.

Blood Adv. 2019 Jul 9;3(13):2013-2021. doi: 10.1182/bloodadvances.2019000251.

15.

Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report.

Flaherty D, Connors JM, Singh S, Sylvester KW, Rimsans J, Cornella L.

A A Pract. 2019 Oct 1;13(7):271-273. doi: 10.1213/XAA.0000000000001052.

PMID:
31265446
16.

Stepped-wedge randomised trial to evaluate population health intervention designed to increase appropriate anticoagulation in patients with atrial fibrillation.

Wang SV, Rogers JR, Jin Y, DeiCicchi D, Dejene S, Connors JM, Bates DW, Glynn RJ, Fischer MA.

BMJ Qual Saf. 2019 Oct;28(10):835-842. doi: 10.1136/bmjqs-2019-009367. Epub 2019 Jun 26.

PMID:
31243156
17.

Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis.

Connell NT, Connors JM.

J Thromb Thrombolysis. 2019 Oct;48(3):382-386. doi: 10.1007/s11239-019-01903-z.

PMID:
31228036
18.

Prothrombin Complex Concentrate for Warfarin Reversal in Patients with Continuous-Flow Left Ventricular Assist Devices: A Narrative Review.

Jennings DL, Rimsans J, Connors JM.

ASAIO J. 2019 Jun 5. doi: 10.1097/MAT.0000000000001021. [Epub ahead of print]

PMID:
31192853
19.

Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial.

Bansal A, Uriel N, Colombo PC, Narisetty K, Long JW, Bhimaraj A, Cleveland JC Jr, Goldstein DJ, Stulak JM, Najjar SS, Lanfear DE, Adler ED, Dembitsky WP, Somo SI, Crandall DL, Chen D, Connors JM, Mehra MR.

J Heart Lung Transplant. 2019 Aug;38(8):806-816. doi: 10.1016/j.healun.2019.05.006. Epub 2019 May 17.

PMID:
31147187
20.

Hodgkin lymphoma, treatment and thrombosis: A dangerous mix.

Connors JM.

Ann Oncol. 2019 May 27. pii: mdz174. doi: 10.1093/annonc/mdz174. [Epub ahead of print] No abstract available.

PMID:
31132097
21.

Low-intensity anti-coagulation using Vitamin K antagonists and Factor X activity: A validation analysis of the MAGENTUM-1 study.

Connors JM, Gregor S, Crandall D, Netuka I, Mehra MR.

J Heart Lung Transplant. 2019 Jun;38(6):668-669. doi: 10.1016/j.healun.2019.02.013. No abstract available.

PMID:
31128601
22.

To treat or not to treat, that is the NLPHL question.

Connors JM.

Blood. 2019 May 16;133(20):2113-2114. doi: 10.1182/blood-2019-02-900811. No abstract available.

PMID:
31097532
23.

Andexanet Alfa (Andexxa) Formulary Review.

Beik N, Reddy P, Sylvester KW, Connell NT, Giugliano RP, Piazza G, Connors JM.

Crit Pathw Cardiol. 2019 Jun;18(2):66-71. doi: 10.1097/HPC.0000000000000177.

PMID:
31094731
24.

Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study.

Kearon C, Parpia S, Spencer FA, Schulman S, Stevens SM, Shah V, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Connors JM, Ginsberg JS, Spadafora L, Julian JA.

J Thromb Haemost. 2019 Jul;17(7):1144-1152. doi: 10.1111/jth.14458. Epub 2019 May 20.

PMID:
31033194
25.

Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support.

Levesque AA, Lewin AR, Rimsans J, Sylvester KW, Coakley L, Melanson F, Mallidi H, Mehra M, Givertz MM, Connors JM.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619837362. doi: 10.1177/1076029619837362.

26.

Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.

Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, Sehn LH, Connors JM, Gascoyne RD, Feldman AL, Farinha P, Steidl C, Scott DW, Slack GW, Savage KJ.

Br J Haematol. 2019 Aug;186(3):e28-e31. doi: 10.1111/bjh.15860. Epub 2019 Mar 14. No abstract available.

PMID:
30873584
27.

Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas.

Ellin F, Maurer MJ, Srour L, Farooq U, Jerkeman M, Connors JM, Smedby KE, Bennani NN, Ansell SM, Slack GW, Cerhan JR, Relander T, Feldman AL, Savage KJ.

Br J Haematol. 2019 Aug;186(3):e24-e27. doi: 10.1111/bjh.15859. Epub 2019 Mar 11. No abstract available.

PMID:
30859549
28.

Derivation and Validation of Age- and Body Mass Index-Adjusted Weight-Based Unfractionated Heparin Dosing.

Schurr JW, Muske AM, Stevens CA, Culbreth SE, Sylvester KW, Connors JM.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619833480. doi: 10.1177/1076029619833480.

29.

Antifibrinolytic Agents for Hemoptysis Management in Adults With Cystic Fibrosis.

Al-Samkari H, Shin K, Cardoni L, Pighetti EH, Rits S, McMahon L, Perkins R, Uluer A, Connors JM.

Chest. 2019 Jun;155(6):1226-1233. doi: 10.1016/j.chest.2019.02.010. Epub 2019 Feb 18.

PMID:
30790551
30.

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.

Ennishi D, Takata K, BĂ©guelin W, Duns G, Mottok A, Farinha P, Bashashati A, Saberi S, Boyle M, Meissner B, Ben-Neriah S, Woolcock BW, Telenius A, Lai D, Teater M, Kridel R, Savage KJ, Sehn LH, Morin RD, Marra MA, Shah SP, Connors JM, Gascoyne RD, Scott DW, Melnick AM, Steidl C.

Cancer Discov. 2019 Apr;9(4):546-563. doi: 10.1158/2159-8290.CD-18-1090. Epub 2019 Jan 31.

PMID:
30705065
31.

Overcoming barriers to integrating direct oral anticoagulants into existing anticoagulation management services.

Sylvester KW, Connors JM.

Res Pract Thromb Haemost. 2018 Dec 12;3(1):136-137. doi: 10.1002/rth2.12171. eCollection 2019 Jan. No abstract available.

32.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.

Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ.

Clin Cancer Res. 2019 Mar 15;25(6):1718-1726. doi: 10.1158/1078-0432.CCR-18-2435. Epub 2019 Jan 7.

PMID:
30617130
33.

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P, Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S, Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW.

J Clin Oncol. 2019 Jan 20;37(3):190-201. doi: 10.1200/JCO.18.01583. Epub 2018 Dec 3.

PMID:
30523716
34.

Resource utilization and hospital readmission associated with gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices.

Carnicelli AP, Thakkar A, Deicicchi DJ, Storm AC, Rimsans J, Connors JM, Mehra MR, Groarke JD, Givertz MM.

J Thromb Thrombolysis. 2019 Apr;47(3):375-383. doi: 10.1007/s11239-018-1781-4.

PMID:
30523584
35.

Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis.

DiRisio AC, Harary M, Muskens IS, Yunusa I, Gormley WB, Aglio LS, Smith TR, Connors JM, Mekary RA, Broekman MLD.

J Clin Neurosci. 2019 Apr;62:188-194. doi: 10.1016/j.jocn.2018.11.032. Epub 2018 Nov 22.

PMID:
30472344
36.

Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.

Chapuy CI, Kaufman RM, Alyea EP, Connors JM.

N Engl J Med. 2018 Nov 8;379(19):1846-1850. doi: 10.1056/NEJMoa1807438. Erratum in: N Engl J Med. 2019 Jan 17;380(3):302.

PMID:
30403942
37.

Letter comments on a published article in the New England Journal of Medicine.

Connors JM, Radford J.

Eur J Cancer. 2018 Nov;104:250-251. doi: 10.1016/j.ejca.2018.09.020. Epub 2018 Oct 23. No abstract available.

PMID:
30361101
38.

Andexanet alfa-The first 150 days.

Culbreth SE, Rimsans J, Sylvester K, Pallin DJ, Connors JM.

Am J Hematol. 2019 Jan;94(1):E21-E24. doi: 10.1002/ajh.25326. Epub 2018 Nov 26. No abstract available.

PMID:
30358896
39.

Betrixaban in the prevention of venous thromboembolism in medically ill patients.

Sylvester KW, Connors JM.

Future Cardiol. 2018 Nov;14(6):455-470. doi: 10.2217/fca-2018-0052. Epub 2018 Oct 24. Review.

PMID:
30353749
40.

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Chong LC, Ben-Neriah S, Slack GW, Freeman C, Ennishi D, Mottok A, Collinge B, Abrisqueta P, Farinha P, Boyle M, Meissner B, Kridel R, Gerrie AS, Villa D, Savage KJ, Sehn LH, Siebert R, Morin RD, Gascoyne RD, Marra MA, Connors JM, Mungall AJ, Steidl C, Scott DW.

Blood Adv. 2018 Oct 23;2(20):2755-2765. doi: 10.1182/bloodadvances.2018023572.

41.

Response by Netuka et al regarding the article "Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump-the MAGENTUM 1 study".

Netuka I, Connors JM, Mehra MR; MAGENTUM 1 investigators.

J Heart Lung Transplant. 2018 Oct;37(10):1279-1280. doi: 10.1016/j.healun.2018.07.017. Epub 2018 Aug 4. No abstract available.

PMID:
30293619
42.

Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.

Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L, Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B, Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB, Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD.

Nat Commun. 2018 Oct 1;9(1):4001. doi: 10.1038/s41467-018-06354-3.

43.

Venous thromboembolism incidence in hematologic malignancies.

Kekre N, Connors JM.

Blood Rev. 2019 Jan;33:24-32. doi: 10.1016/j.blre.2018.06.002. Epub 2018 Jun 21. Review.

PMID:
30262170
44.

Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM.

Blood. 2018 Nov 29;132(22):2401-2405. doi: 10.1182/blood-2018-05-851154. Epub 2018 Sep 26.

PMID:
30257882
45.

Hemorrhagic Highs from Synthetic Cannabinoids - A New Epidemic.

Connors JM.

N Engl J Med. 2018 Sep 27;379(13):1275-1277. doi: 10.1056/NEJMe1810418. No abstract available.

PMID:
30257159
46.

Postoperative bridging anticoagulation and left ventricular assist system thrombosis.

Nemer DM, Stewart GC, Puligandla M, Neuberg DS, Givertz MM, Mehra MR, Couper GS, Connors JM.

J Thromb Thrombolysis. 2019 Jan;47(1):57-66. doi: 10.1007/s11239-018-1746-7.

PMID:
30255419
47.

Advanced-Stage Hodgkin Lymphoma: New Approaches Based on Novel Therapeutic Agents or Treatment Intensification.

Connors JM.

Cancer J. 2018 Sep/Oct;24(5):230-236. doi: 10.1097/PPO.0000000000000333. Review.

PMID:
30247258
48.

Introduction From the Guest Editor: Hodgkin Lymphoma: Integrating New Therapies to Improve Outcomes.

Connors JM.

Cancer J. 2018 Sep/Oct;24(5):205. doi: 10.1097/PPO.0000000000000335. No abstract available.

PMID:
30247254
49.

New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?

Spinner MA, Advani RH, Connors JM, Azzi J, Diefenbach C.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:626-636. doi: 10.1200/EDBK_200679. Review.

PMID:
30231319
50.

Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.

Chihara D, Wong S, Feldman T, Fanale MA, Sanchez L, Connors JM, Savage KJ, Oki Y.

Hematol Oncol. 2019 Feb;37(1):35-38. doi: 10.1002/hon.2560. Epub 2018 Oct 23.

PMID:
30209819

Supplemental Content

Loading ...
Support Center